
## **Michael Nauck**

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/10952378/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Report from the CVOT Summit 2021: new cardiovascular, renal, and glycemic outcomes. Cardiovascular Diabetology, 2022, 21, 50.	6.8	8
2	Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet, The, 2019, 394, 39-50.	13.7	315
3	Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet, The, 2018, 392, 1519-1529.	13.7	1,179
4	Risk of hypoglycaemia in people aged ≥65Âyears receiving linagliptin: pooled data from 1489 individuals with type 2 diabetes mellitus. International Journal of Clinical Practice, 2018, 72, e13240.	1.7	5
5	Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial. Diabetes Care, 2016, 39, 1501-1509.	8.6	126
6	Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2015, 58, 429-442.	6.3	598
7	Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care, 2015, 38, 140-149.	8.6	2,326
8	Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care, 2014, 37, 2149-2158.	8.6	236
9	Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study. Lancet, The, 2013, 381, 117-124.	13.7	466
10	Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach. Diabetes Care, 2012, 35, 1364-1379.	8.6	3,077
11	Liraglutide Treatment Is Associated with a Low Frequency and Magnitude of Antibody Formation with No Apparent Impact on Glycemic Response or Increased Frequency of Adverse Events: Results from the Liraglutide Effect and Action in Diabetes (LEAD) Trials. Journal of Clinical Endocrinology and Metabolism, 2011, 96, 1695-1702.	3.6	125
12	Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet, The, 2010, 375, 1447-1456.	13.7	534
13	Adding Liraglutide to Oral Antidiabetic Drug Monotherapy: Efficacy and Weight Benefits. Postgraduate Medicine, 2009, 121, 5-15.	2.0	27
14	Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes. Diabetes Care, 2009, 32, 84-90.	8.6	991
15	Gut hormones and diabetes mellitus. Diabetes/metabolism Reviews, 1992, 8, 149-177.	0.3	162
16	Insulinotropic Properties of Synthetic Human Gastric Inhibitory Polypeptide in Man: Interactions with Glucose, Phenylalanine, and Cholecystokinin-8. Journal of Clinical Endocrinology and Metabolism, 1989, 69, 654-662.	3.6	105